Exicure faces a precarious outlook as it operates without any revenue generation, evidenced by multiple quarters of zero top-line growth. The company's reliance on a non-productive cost structure, with quarterly operating expenses consistently exceeding $1.5 million, continues to erode its remaining $2.6 million cash…
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.18+99.0% vs -$18.60 | — vs $2M |
Q2 2026 May 29, 2026 | -$0.29+98.4% vs -$18.60 | — vs $2M |
Q2 2026 Mar 25, 2026 | -$0.46+51.6% vs -$0.95 | $22M+458.3% vs $4M |
Q4 2025 Nov 7, 2025 | -$0.39+91.3% vs -$4.50 | $2M-48.3% vs $4M |
Shattuck Labs (NASDAQ: STTK - Get Free Report) and Exicure (NASDAQ: XCUR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability. Risk and Volatility Shattuck Labs has a beta
WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1).
Benchmark XCUR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Exicure, Inc. (XCUR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.95 | $6.05M | -0.73 | -100% | — | -237.91% | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $58.16 | $8.19B | -26.06 | 23258.15% | -47.79% | -60.05% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — |
Exicure, Inc. (XCUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Exicure, Inc. (XCUR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 30, 2026·SEC
Jun 1, 2026·SEC
Apr 10, 2026·SEC
Get notified when XCUR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Exicure, Inc. (XCUR) stock FAQ — growth, dividends, profitability & financials explained
Exicure, Inc. (XCUR) revenue fell by 100.0% in fiscal year 2025, compared with the prior fiscal year.
No. Exicure, Inc. (XCUR) reported a net loss of $8.3M over the trailing twelve months.
Exicure, Inc. (XCUR) had a return on equity (ROE) of -237.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Exicure, Inc. (XCUR) had negative free cash flow of $6.4M over the trailing twelve months.
